Home Blog Page 1194

Pacific Century Premium Developments Limited announces annual results for the financial year ended December 31, 2025

By
Advertorial Desk
-

HONG KONG SAR – Media OutReach Newswire – 9 February 2026

2025 Annual Results – Financial Highlights

(Figures for the corresponding period in 2024 are shown in brackets)

  • Consolidated revenue: HK$1,046million (HK$695million)
  • Consolidated net loss attributable to equity holders of the Company:
    HK$    69 million (HK$230million)
  • Basic loss per share: 3.38 HK cents (11.29 HK cents)
  • No final dividend (No final dividend)

Pacific Century Premium Developments Limited (“PCPD”, SEHK: 00432) has announced its annual results for the year ended December 31, 2025.

The consolidated revenue of PCPD and its subsidiaries (together, the “Group”) amounted to HK$ 1,046 million, representing an increase of 51% compared to the revenue of HK$ 695 million in 2024.

The consolidated net loss attributable to equity holders of the Company for the year of 2025 was HK$ 69 million, compared to the net loss of HK$ 230 million in 2024.

Basic loss per share for 2025 was 3.38 Hong Kong cents compared to the loss per share of 11.29 Hong Kong cents for the previous year.

The Board of Directors has not recommended the payment of a final dividend for the year ended December 31, 2025.

In 2025, PCPD achieved robust full-year results, driven by the sustained surge in international travel across our key Asian markets, our operational strengths, and the continued recognition of our high-quality portfolio. This performance was underpinned predominantly by contributions from two segments: Park Hyatt Niseko, Hanazono, our hospitality business in Hokkaido, which delivered a notable rise in occupancy and revenue, and our ski and recreation operations in Niseko, Hokkaido, which also saw a surge in demand and revenue.

Park Hyatt Niseko, Hanazono, our hotel operations in Hokkaido, delivered a robust performance in 2025, as the boom in Japan‘s tourism sector continued throughout the year, again with record-breaking tourist arrivals. The average occupancy rate of Park Hyatt Niseko increased by 4 percentage points.

During the winter season of 2024/2025, total ski-lift and gondola rides increased 9% year-on-year. The travel surge continued to drive robust demand for our recreational business in Niseko well beyond the cold months.

In Phang Nga, Thailand, the Group has sold or reserved 40% of Phase 1A villas. The Group’s revenue from its property development in Thailand totalled HK$14 million for the year ended December 31, 2025, compared to no revenue in 2024.

We formed a strategic alliance with Hotel Properties Limited in Singapore to bring a Four Seasons Resort and Branded Residences to the prestigious integrated resort community of Aquella in Phang Nga. The move represents a significant milestone in PCPD‘s long-term vision of transforming Aquella into a visionary integrated resort destination that effortlessly blends luxury living, recreation and exceptional service.

In Jakarta, Indonesia, the occupancy of our premium commercial building, Pacific Century Place, Jakarta (“PCP Jakarta”), was stable throughout the year, and the project remained a consistent revenue contributor to the Group. As of December 31, 2025, the office space committed occupancy was 87%, compared to 85% in the previous year.

Development of the superstructure of the Group‘s project at 3–6 Glenealy, Central, Hong Kong, has been progressing well. We have reached a key structural milestone, with the superstructural work now completed and installation of the curtain walls progressing at pace. The name of the development has also been unveiled as “Central Residence by the Park”, and its completion is scheduled for the first half of 2026.

In the long run, we remain cautiously optimistic about the long-term outlook for property sectors in Hong Kong, Japan, Thailand and Indonesia. With PCPD‘s disciplined execution and proactive risk management, we have confidence in our ability to drive continued growth and deliver sustained value.

Mr. Benjamin Lam, PCPD’s Deputy Chairman and Group Managing Director, said: “We will maintain our prudent yet proactive approach, allocating resources carefully and pursuing value-enhancing initiatives. Our priority remains to drive sustainable growth, improve profitability, and deliver solid returns to shareholders and stakeholders.”

Hashtag: #PacificCenturyPremiumDevelopments

The issuer is solely responsible for the content of this announcement.

About PCPD

Pacific Century Premium Developments Limited (“PCPD” or the “Group”, SEHK: 00432) is principally engaged in the development and management of premium-grade property and infrastructure projects as well as premium-grade property investments. PCCW Limited (“PCCW”, SEHK: 00008) is the single largest shareholder of the Group.

Global e∙dentity™ Announces End of Conditional Licensing Agreement with FDI Advisory Group

By
Advertorial Desk
-

CUPERTINO, Calif., Feb. 9, 2026 /PRNewswire/ — Global e∙dentity™, a Delaware corporation and leading innovator in multi-factor biometric identity IP-based solutions, today announced that it has ended its November 2025 conditional exclusive global banking licensing and sales agreement that it had granted to FDI Advisory Group (www.fdiadvisorygroup.com) for mobile banking applications, effective January 30, 2026. No details regarding the termination will be disclosed. Any and all affected customers have been notified of the matter.

Global e∙dentity™ remains committed to advancing its patented quantum-resilient vein biometric technologies and is actively pursuing new strategic opportunities to deliver secure, living identity solutions to the global banking and airport sectors.

About Global e∙dentity™ 

Global e∙dentity™ Inc. is a registered corporation in Delaware and a leading provider of multi-factor biometrics, digital identity solutions, and Airport biometrics. For more information, please visit www.globaledentity.com. Global e∙dentity™ and its product(s) are either registered trademarks or trademarks of Global e∙dentity™ Inc. in the United States and/or other countries.

Global e∙dentity™ Corporate Communications 

Sophia Miller 

Email: somiller@globaledentity.com

DIFF Biotech’s Innovative Nasal Spray Influenza Vaccine Receives Clinical Trial Approval, Introducing a New Attenuation Pathway

By
Advertorial Desk
-

HANGZHOU, China, Feb. 9, 2026 /PRNewswire/ — Zhejiang Difference Biological Technology Co., Ltd. (DIFF Biotech) announced that its proprietary nasal spray influenza attenuated live vaccine, DIFF-flu, has recently received clinical trial approval as a Class 1.2 innovative vaccine from China’s National Medical Products Administration (NMPA).

As the first domestically self-developed nasal spray influenza vaccine in China to advance into clinical trial, DIFF-flu leverages a pioneering M2 gene–modified attenuation technology, protected by multiple international invention patents. This achievement underscores DIFF Biotech’s leading capabilities in respiratory infectious disease prevention and establishes an important foundation for future industrialization.

Dr. Jiasheng Song, Chief Executive Officer of DIFF Biotech, commented: “DIFF-flu’s clinical approval marks a major milestone for DIFF Biotech and a meaningful achievement for independent innovation in respiratory infectious disease prevention. As a next-generation attenuation platform, DIFF-flu is designed to achieve an optimal balance between immunogenicity and safety—an advance that holds significant potential for improving influenza protection. We believe this progress will help expand access to safer, more effective influenza prevention, particularly for older adults and other vulnerable populations. DIFF Biotech will continue to drive next-generation vaccine innovation to strengthen public health and contribute to global biomedical progress.”

A New Attenuation Strategy: Replication Restriction for Enhanced Safety

DIFF-flu is developed using an innovative M2 gene–modification strategy that produces a replication-restricted vaccine strain. This approach achieves a deliberate balance between robust attenuation and strong immunogenicity—generating a potent immune response while maintaining an exceptional safety profile. In essence, the technology places a “safety harness” on the virus to prevent uncontrolled replication.

Existing nasal spray influenza vaccines on the market rely on cold-adapted attenuation, allowing the vaccine virus to replicate efficiently only at lower temperatures such as those in the nasal cavity but limiting replication in the warmer lower respiratory system and lungs. Because these strains can still replicate in nasal mucosa and cause mild viral shedding, they are generally not recommended for older adults or immunocompromised individuals.

Preclinical data indicate that DIFF-flu offers a differentiated safety profile, with negligible viral shedding, and significantly reduced viral loads in respiratory tissues, suggesting the potential to extend nasal spray vaccine eligibility to older adults and other underserved groups.

Notably, preclinical data show that DIFF-flu confers 100% protection against epidemic strains circulating more than 50 years ago, while also eliciting strong immunity against contemporary variants.

Market Landscape: At-Home Use Policies Unlock Global Opportunities

The global influenza vaccine market is undergoing a period of structural evolution. While injectable vaccines remain the predominant format, they continue to face long-standing challenges such as suboptimal uptake and limited ability to curb viral transmission. Nasal spray vaccines—which induce mucosal immunity directly at the site of viral entry—represent an increasingly important direction for influenza prevention.

In September 2024, the U.S. FDA granted authorization for at-home administration of a related nasal spray influenza vaccine, paving the way for direct-to-consumer (DTC) distribution models. This regulatory milestone significantly improves convenience and accessibility for the public and creates favorable conditions for DIFF-flu’s future global introduction.

Global Influenza Burden Underscores the Need to Strengthen Herd Immunity

According to the World Health Organization (WHO), seasonal influenza infects up to 1 billion people each year, causing 3–5 million severe cases and 290,000–650,000 respiratory deaths globally.

Older adults account for the majority of influenza-related deaths and face heightened risks of complications such as pneumonia, myocarditis, encephalitis, and acute cardiorespiratory failure. Studies show that influenza vaccination can reduce hospitalization risk by 40–60%, making improved vaccine coverage especially critical for aging and medically vulnerable populations.

Despite this, vaccination rates remain low in many parts of the world. In China, influenza vaccination coverage is approximately 3.8%, far below mature markets such as the United States (around 49.3%). Increasing vaccination uptake is essential to protect high-risk groups and strengthen community-level immunity.

About DIFF Biotech

Zhejiang Difference Biological Technology Co., Ltd. (DIFF Biotech) is a clinical-stage biotechnology company specializing in its proprietary Viraltech Architect Platform. Leveraging this platform, the company has built an integrated, end-to-end capability for the development of differentiated biologics. DIFF Biotech has filed over 70 domestic and international invention patents, including more than 10 PCT applications, and has received multiple honors such as the 23rd China Excellent Patent Award, “High-tech Enterprise” and “Quasi-Unicorn” enterprise.

The company’s R&D efforts span mucosal vaccines, antiviral drugs, oncolytic viruses, and gene therapy products. Its vaccine pipeline—powered by proprietary attenuation technologies—effectively establishes the body’s first line of defense at the mucosal barrier, offering clear competitive differentiation. In the oncolytic virus and gene therapy domains, DIFF Biotech has built distinctive capabilities in vector targeting, controllable replication, and high-efficiency gene delivery, enabling the development of advanced, next-generation biologics.

 For more information, please visit https://en.diff-biotech.com/.

E-mail: BD@diff-biotech.com 

 

BioDlink Recognized by Client for Enabling the World’s First Dual-Payload ADC to Enter Clinical Trials

By
Advertorial Desk
-
  • BioDlink received a formal letter of appreciation from Chengdu Kanghong Pharmaceutical Group for its contribution to advancing KH815, the world’s first dual-payload antibody–drug conjugate (ADC) to enter clinical development.
  • BioDlink enabled IND approval 1.5 months ahead of schedule through efficient process development, manufacturing, and analytical execution.

SUZHOU, China, Feb. 9, 2026 /PRNewswire/ — BioDlink announced that it has received a formal letter of appreciation from its client, Chengdu Kanghong Pharmaceutical Group (“Kanghong Pharmaceutical”), recognizing BioDlink’s critical contribution to the successful clinical approval of KH815, the world’s first dual-payload antibody–drug conjugate (ADC) to enter clinical development.

KH815 is a first-in-class dual-payload ADC independently developed by Kanghong Pharmaceutical. The program achieved a major regulatory milestone with approval from Australia’s Human Research Ethics Committee (HREC) on March 21, 2025 followed by clinical trial authorization in China on April 15, 2025.

As Kanghong Pharmaceutical’s CDMO partner, BioDlink supported the program across the full development lifecycle, including process development, analytical method development and validation, and formulation research.

Efficient Execution of a Complex First-in-Class Program

KH815 required advanced process design and analytical control, including precise management of drug-to-antibody ratio (DAR) and comprehensive product characterization. Leveraging its expertise in complex ADC development, BioDlink delivered a robust, scalable, and reproducible manufacturing solution despite limited material availability and aggressive timelines.

Despite the complexity of conjugation process development and analytical characterization, BioDlink applied strong technical expertise to define and lock robust process and analytical strategies, enabling successful scale-up and batch release. Through continuous process optimization, development, manufacturing, and regulatory submission activities were completed 1.5 months ahead of plan, exceeding client expectations and demonstrating strong execution capability, which earned high recognition from Kanghong Pharmaceutical for BioDlink’s technical expertise and service excellence.

Advancing Innovation in ADC Development

The successful progression of KH815 underscores the growing potential of dual-payload ADC technologies and highlights the value of close collaboration across industry and research. BioDlink remains committed to providing end-to-end CDMO services to global partners, accelerating the development of complex biologics from early development through commercialization.

About Kanghong Pharmaceutical
Kanghong is a publicly traded pharmaceutical company based in the province of Sichuan, China. It was founded in 1996 and researches, develops, manufactures, and distributes medicines for ophthalmic, neuropsychiatric and others.

Kanghong is devoted to the lives of patients through high quality, innovation and responsibility. Since its establishment, the company keeps researching, producing, and commercializing safer and more efficient drugs for pressing unmet medical needs.

The company’s purpose is to fundamentally improve patients’ physical ability and social medical efficacy by using innovative science and breakthrough treatments to achieve  progress in human health.

About BioDlink
BioDlink (1875.HK) is a leading global CDMO specializing in biologics and bioconjugates (ADCs/XDCs). Headquartered in Suzhou with centers in Shanghai and Beijing, the company provides fully integrated, end-to-end services spanning early R&D through commercial manufacturing.

With its one-base integrated platform and proprietary technologies—such as BDKcell® for rapid cell line development and GL-DisacLink® for site-specific conjugation—BioDlink helps partners accelerate development, improve efficiency, and reduce costs.

The company operates four commercial manufacturing lines with large-scale sterile fill-finish capabilities, backed by a global GMP-aligned quality system that has earned PMDA accreditation in Japan and supported product approvals across China, Indonesia, Nigeria, Pakistan, Colombia and Bolivian.

Guided by the philosophy of “Quality First, Innovation Driven, Success Together”, BioDlink is committed to advancing global access to next-generation biologics and building trusted partnerships worldwide. For more information, please visit: https://biodlink.com/ 

Acer Announces January 2026 Revenues at NT$21.08 Billion, Up 39.8% Year-on-year, Highest January Revenue Post Pandemic

By
Advertorial Desk
-

TAIPEI, Feb. 9, 2026 /PRNewswire/ — Acer Inc. (TWSE: 2353) announced its consolidated revenues for January 2026 at NT$21.08 billion, up 39.8% year-on-year (YoY), the highest January revenue post pandemic.

Highlights in January include:

  • Revenues from notebook PCs grew by 50.6% YoY
  • Revenues from desktop PCs grew by 41.9% YoY
  • Revenues from gaming products and businesses grew by 53.4% YoY
  • Revenues from the commercial line [1] grew by 63.4%

Acer’s strategy to expand multiple business engines continued to gain momentum. Total revenues from businesses other than personal computers [2] and displays contributed 42.1% of the group’s total revenues in January. Acer’s public subsidiaries have announced their January revenues; some highlights for businesses under incubation include Acer ITS Inc. with revenues growth of 83.0% year-on-year in January.

The Acer Chromebooks released during the BETT 2026 education technology exhibition in London were well received by the media, who highlighted their durable designs and repairability features that are beneficial for school teaching and IT teams for repairs. Acer ranked among the top 3 in the global Chromebook market, and No. 1 in EMEA in full year 2025 [3].

[1] Acer’s commercial products, excluding Chromebooks
[2] Personal computers business includes desktops and notebooks
[3] IDC Preliminary Historical Q4’25 PC report

About Acer

Founded in 1976, Acer is one of the world’s top technology companies with a presence in more than 160 countries. The company continues to evolve by embracing innovation across its offerings, which include computers and displays, while branching out to new businesses. Acer is also committed to sustainable growth, exploring new opportunities that align with its environmental and social responsibilities. The Acer Group employs nearly 12,000 employees that contribute to the research, design, marketing, sales and support of products, solutions, and services that break barriers between people and technology. Visit www.acer.com for more information.

© 2026 Acer Inc. All rights reserved. Acer and the Acer logo are registered trademarks of Acer Inc. Other trademarks, registered trademarks, and/or service marks, indicated or otherwise, are the property of their respective owners. All offers subject to change without notice or obligation and may not be available through all sales channels. Prices listed are manufacturer suggested retail prices and may vary by location. Applicable sales tax extra.

DAR GLOBAL DEBUTS NICKELODEON HOTELS & RESORTS OMAN IN AIDA, THE ICONIC BRAND OF FAMILY ENTERTAINMENT

By
Advertorial Desk
-

MUSCAT, Sultanate of Oman, Feb. 9, 2026 /PRNewswire/ — Dar Global, the London-listed luxury real estate developer, has unveiled Nickelodeon Hotels & Resorts Oman at its landmark AIDA development. The project marks a significant addition to Oman’s fast-growing tourism sector, redefining luxury family travel while presenting a distinctive investment opportunity within one of the Sultanate’s most ambitious destinations.

DAR GLOBAL DEBUTS NICKELODEON HOTELS & RESORTS OMAN IN AIDA, THE ICONIC BRAND OF FAMILY ENTERTAINMENT
DAR GLOBAL DEBUTS NICKELODEON HOTELS & RESORTS OMAN IN AIDA, THE ICONIC BRAND OF FAMILY ENTERTAINMENT

Located 130 metres above sea level within AIDA’s clifftop community, the resort blends high-end hospitality with immersive, family-focused entertainment. The Nickelodeon Hotel will feature 120 keys, comprising furnished themed luxury suites and family-oriented rooms ranging from one-bedroom units to expansive three-bedroom residences, each designed with bold character and playful detailing inspired by Nickelodeon’s globally recognised brands.

Guests and residents will enjoy access to Aqua Nick, a signature waterpark with slides and splash zones, alongside themed dining concepts, Club Nick—the hotel’s dedicated kids-only clubhouse—and a programme of live entertainment including interactive game shows, character appearances and Nickelodeon’s iconic slime experiences.

For investors, the project offers full title ownership within a globally recognised branded family hospitality concept, designed to drive strong demand, long-term appeal and attractive returns.

Nickelodeon Hotels & Resorts Oman forms part of the wider AIDA masterplan, a joint venture between Dar Global and Omran Group, Oman’s leading tourism development entity. Spanning 3.5 million square metres, AIDA integrates luxury golf, residential and hospitality offerings, including mansions, limited-edition villas and premium apartments, reinforcing Oman’s positioning as a destination for high-quality living, tourism and investment.

Ziad El Chaar, CEO of Dar Global, said: “AIDA is a milestone project that elevates Oman’s luxury real estate landscape and supports long-term economic growth. The introduction of Nickelodeon Hotels & Resorts Oman reflects our commitment to delivering distinctive destinations and compelling investment opportunities aligned with global demand.”

Marie Marks, Senior Vice President, Global Experiences, Paramount, added: “Nickelodeon Hotels & Resorts Oman will offer families and fans an unforgettable destination, combining world-class entertainment with thoughtfully designed accommodation that creates lasting memories.”

Aligned with Oman Vision 2040, the development supports national objectives to expand tourism and diversify GDP. With the first phase of AIDA, including core infrastructure, scheduled for completion by 2027, early investors stand to benefit from entry into a rapidly emerging luxury destination supported by Dar Global’s proven track record in branded residential and hospitality developments.

AV-Comparatives Publishes Security Survey 2026: Global Trends in Cybersecurity Adoption and Threat Perception

By
Advertorial Desk
-

INNSBRUCK, Austria, Feb. 9, 2026 /PRNewswire/ — AV-Comparatives, the leading independent authority on cybersecurity testing and research, today announced the release of the Security Survey 2026, a comprehensive global study capturing current user behavior, technology preferences, and threat perceptions in IT security. Based on responses from 1,328 participants across 87 countries, the survey provides a data-driven snapshot of how individuals and organizations approach digital protection in an evolving threat landscape.

 

 

Most-Used Desktop Security Solutions

One of the key findings of the survey is the continued reliance on a small group of established desktop security vendors. A clear majority of respondents report using commercial or paid security solutions, indicating a sustained preference for comprehensive protection over free alternatives. Among the most widely used desktop security products are Bitdefender, Kaspersky and ESET, with Microsoft’s security solutions also playing a significant role.

These results underline the importance of trust, brand recognition and proven testing results in users’ security choices, while also revealing regional differences in vendor adoption.

Operating Systems and Platform Trends

The survey highlights ongoing shifts in operating system usage. Windows 11 is now the most used desktop operating system among respondents, reflecting continued migration away from older, now unsupported, Windows versions. In parallel, the data shows that Linux usage has reached levels comparable to macOS within the survey population, suggesting a growing acceptance of Linux as a viable desktop platform among security-aware users.

On mobile devices, Android maintains its dominant position globally, while iOS continues to attract a strong user base, particularly among professionals and advanced users.

Perceived Sources of Cyberattacks

Beyond technology adoption, the Security Survey 2026 provides insight into how users perceive global cyber threats. When asked which countries they most fear as potential sources of cyberattacks, respondents most frequently named Russia and China, followed by the United States and North Korea.

Additionally, a notable proportion of participants expressed concern about domestic surveillance and internal threats within their own countries.

Practical Insights for the Security Community

While the survey is not intended to represent the global population as a whole, it offers valuable insights for cybersecurity professionals, vendors, researchers and policymakers. Trends such as the continuing preference of commercial security solutions, the dominance of Windows 11, the growing relevance of Linux, and evolving perceptions of state-sponsored threat actors provide meaningful context for strategic decision-making.

Access the Full Report

The AV-Comparatives Security Survey 2026 is available free of charge and without registration at:
https://www.av-comparatives.org/av-comparatives-security-survey-2026-published/

Cango Inc. Releases 2025 Letter to Shareholders

By
Advertorial Desk
-

DALLAS, Feb. 9, 2026 /PRNewswire/ — Cango Inc. (NYSE: CANG) today released a letter to shareholders highlighting its strategic transformation and roadmap to evolve from a global Bitcoin miner into an AI compute infrastructure platform.

Throughout the past year, Cango executed a disciplined entry into the industry, balancing speed with operational prudence to build its position as a leading Bitcoin miner with a global footprint across four key regions. Key commitments were delivered, including acquiring and enhancing hashrate efficiency of 50 EH/s of on-rack machines, adopting a strategic treasury approach, divesting legacy operations, securing 50 MW of energy infrastructure, and completing the transition to a direct NYSE listing. These milestones established the foundation for Cango’s transition from hosted hashpower toward a global distributed inference compute grid.

In response to market conditions, Cango made a treasury adjustment to strengthen the balance sheet and reduce financial leverage, creating increased capacity to fund strategic expansion into AI compute infrastructure.

The Strategic Logic behind the Proposed Pivot

Cango’s global mining operations, operational experience, and infrastructure provide a practical pathway toward AI compute objectives. The rapidly growing AI era continues to face a “Power Gap”—a disconnect between rising compute demand and existing grid capacity. By leveraging globally accessed, grid-connected infrastructure, Cango is positioned to deliver flexible, high-performance compute capacity to meet long-tail inference demand through a scalable business model.

This transition follows a disciplined three-phase roadmap:

Near Term: Standardization and efficient deployment of modular, containerized GPU nodes for rapid deployment, offering on-demand compute capacity.

Medium Term: Deployment of a proprietary software platform for orchestration, evolving Cango into an integrated, enterprise-grade network enabler.

Long Term: Global scaling into a mature AI infrastructure platform, activating underutilized power to establish durable, recurring revenue streams.

To accelerate this transition, Cango has established EcoHash Technology LLC, a wholly-owned subsidiary based in Dallas, Texas, dedicated to advancing AI compute initiatives under the leadership of a newly appointed AI CTO.

The Company also positions itself as an “Ecosystem Enabler” for the wider mining industry, providing a practical technical path to adapt existing energy infrastructure for AI operations with manageable upfront commitment.

Cango acknowledges this shift is a multi-year journey, but believes its infrastructure and operational experience provide a clear path to open new, durable revenue streams while complementing its core mining operations.

View original content: https://ir-image.cangoonline.com/ir-documents/2026-02-09_Cango-Inc-Releases-2025-Letter-to-Shareholders.pdf

Investor Relations Contact

Juliet YE, Head of Communications
Cango Inc.
Email: ir@cangoonline.com 

1...1,1931,1941,195...6,599Page 1,194 of 6,599